These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34884736)

  • 1. Malignant and Benign T Cells Constituting Cutaneous T-Cell Lymphoma.
    Nakai S; Kiyohara E; Watanabe R
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganglioside GD3 May Suppress the Functional Activities of Benign Skin T Cells in Cutaneous T-Cell Lymphoma.
    Kume M; Kiyohara E; Matsumura Y; Koguchi-Yoshioka H; Tanemura A; Hanaoka Y; Taminato M; Tashima H; Tomita K; Kubo T; Watanabe R; Fujimoto M
    Front Immunol; 2021; 12():651048. PubMed ID: 33859643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses.
    Harmon CB; Witzig TE; Katzmann JA; Pittelkow MR
    J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):404-10. PubMed ID: 8784277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
    Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
    Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the Voltage-Gated Potassium Channel Kv1.3 in Lesional Skin from Patients with Cutaneous T-Cell Lymphoma and Benign Dermatitis.
    Hu T; Krejsgaard T; Nastasi C; Buus TB; Nansen A; Hald A; Spee P; Nielsen PR; Blümel E; Gluud M; Willerslev-Olsen A; Woetmann A; Bzorek M; Eriksen JO; Ødum N; Rahbek Gjerdrum LM
    Dermatology; 2020; 236(2):123-132. PubMed ID: 31536992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A histo-immunopathologic and prognostic study of erythrodermic cutaneous T-cell lymphoma.
    Vonderheid EC; Kantor GR; Telang GH; Bujanouskas P; Kadin ME
    J Cutan Pathol; 2019 Dec; 46(12):913-924. PubMed ID: 31403211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma.
    Delfau-Larue MH; Laroche L; Wechsler J; Lepage E; Lahet C; Asso-Bonnet M; Bagot M; Farcet JP
    Blood; 2000 Nov; 96(9):2987-92. PubMed ID: 11049975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
    Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
    Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells.
    Rindler K; Bauer WM; Jonak C; Wielscher M; Shaw LE; Rojahn TB; Thaler FM; Porkert S; Simonitsch-Klupp I; Weninger W; Mayerhoefer ME; Farlik M; Brunner PM
    Front Immunol; 2021; 12():666935. PubMed ID: 33968070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
    Bosisio FM; Cerroni L
    Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell receptor beta variable region (V beta) usage in cutaneous T-cell lymphomas (CTCL) in comparison to normal and eczematous skin.
    Potoczna N; Boehncke WH; Nestle FO; Küenzlen C; Sterry W; Burg G; Dummer R
    J Cutan Pathol; 1996 Aug; 23(4):298-305. PubMed ID: 8864915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
    Wong HK
    G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors.
    Campbell JJ; Clark RA; Watanabe R; Kupper TS
    Blood; 2010 Aug; 116(5):767-71. PubMed ID: 20484084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver.
    Nicolay JP; Albrecht JD; Alberti-Violetti S; Berti E
    Eur J Immunol; 2021 Jul; 51(7):1660-1671. PubMed ID: 33811642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
    Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
    Jarrousse V; Quereux G; Marques-Briand S; Knol AC; Khammari A; Dreno B
    Eur J Dermatol; 2006; 16(6):636-41. PubMed ID: 17229603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.
    Clark RA; Watanabe R; Teague JE; Schlapbach C; Tawa MC; Adams N; Dorosario AA; Chaney KS; Cutler CS; Leboeuf NR; Carter JB; Fisher DC; Kupper TS
    Sci Transl Med; 2012 Jan; 4(117):117ra7. PubMed ID: 22261031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.